CFM
PYXS icon

Catalyst Funds Management’s Pyxis Oncology PYXS Stock Holding History

Catalyst Funds Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.8K Buy
+20,400
New +$30.7K 0.01% 563
2025
Q3 		– Sell
-23,200
Closed -$25.5K – 620
2025
Q2 		$25.5K Buy
+23,200
New +$26.1K 0.01% 413

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Catalyst Funds Management's PYXS Position: Q1 2026 in Review

Catalyst Funds Management opened a new position in Pyxis Oncology (PYXS) in Q1 2026: 20,400 shares worth $29.8K. The stake represents 0.01% of the portfolio and ranks #563 among its holdings. This is a return to the name: Catalyst Funds Management previously reported a position in PYXS as recently as Q2 2025.

Catalyst Funds Management first reported a position in PYXS in Q2 2025 and has held it in 2 quarters since. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Catalyst Funds Management held 20,400 shares of Pyxis Oncology worth $29.8K as of Q1 2026.
  • Pyxis Oncology was a new Catalyst Funds Management position in Q1 2026.
  • Pyxis Oncology made up 0.01% of Catalyst Funds Management's portfolio in Q1 2026, its #563 holding.
  • Catalyst Funds Management first reported a position in Pyxis Oncology in Q2 2025 and has held it in 2 quarters since.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.